HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its HeartBeam System, a tool for assessing potential heart attacks at home. The designation recognizes the potential of HeartBeam's 3D ECG technology to enable physicians to evaluate signs of a possible heart attack when symptoms begin, regardless of the patient's location.
The FDA granted the designation within 30 days of HeartBeam's request, ahead of the agency's 60-day statutory review period. This expedited review underscores the FDA's recognition of the technology's potential to address a significant unmet need in cardiac care. The designation provides prioritized FDA review and interaction as HeartBeam advances its heart attack assessment program and is a prerequisite for certain expedited Medicare coverage pathways.
HeartBeam expects to seek FDA alignment on the design of a multicenter pivotal study in the coming months and anticipates beginning patient enrollment shortly thereafter. If successful, the study is intended to support a future submission to expand the HeartBeam System indications to include heart attack assessment. The company's 3D ECG technology previously received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement.
This news matters because heart attacks are a leading cause of death worldwide, and timely assessment is critical for survival. HeartBeam's cable-free device is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG, which physicians can use to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility. If the technology gains expanded indications, it could significantly reduce the time between symptom onset and treatment, potentially saving lives and reducing healthcare costs.
For investors, the FDA designation is a major milestone that could accelerate the company's path to market and enhance its competitive position. The designation is also a prerequisite for certain Medicare coverage pathways, which could facilitate reimbursement and adoption. HeartBeam's stock (NASDAQ: BEAT) may see increased attention as the company progresses toward a pivotal study. The latest news and updates relating to BEAT are available in the company's newsroom at https://nnw.fm/BEAT.
The announcement was distributed by NetworkNewsWire, a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For more information, visit NetworkNewsWire.
To view the full press release, visit https://nnw.fm/FxKxf. For details on the intended use of HeartBeam's technology, refer to the company's Cleared Indications for Use at https://www.heartbeam.com/indications. Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer.
